Tripartite Therapeutics Inc. (TPEX: 7920)
Health Care · Biotechnology · TW
NT$8.05
-19.26% today · +13.7% 1Y
Tripartite Therapeutics Inc. (TPEX: 7920) operates in the Biotechnology industry within the Health Care sector. The company is valued at $149.44M.
Over the last twelve months the share price has gained 13.7%, trading between 5.91 and 20.60.
7920 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $149.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- NT$20.60
- 52-week low
- NT$5.91
- Avg volume (3M)
- —
- Shares outstanding
- 593.99M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.41 | -0.04% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.54 | +1.91% |
Figures last refreshed Aug 18, 2026.